|
|
|
| Clinical study of transjugular intrahepatic portosystemic shunt for cirrhosis with portal hypertension |
| ZHAO Yulong LIU Shunshun YAO Dejiong LIANG Weijun HUANG Hui WANG Zhongwei |
| Ward Two, General Surgery Department, the First Division Hospital of Xinjiang Production and Construction Corps, Xinjiang Uygur Autonomous Region, Akesu 843000, China |
|
|
|
Abstract Objective To investigate the efficacy of transjugular intrahepatic portosystemic shunt for cirrhosis with portal hypertension. Methods Fifty-four cases of cirrhosis patients with portal hypertension admitted to the First Division Hospital of Xinjiang Production and Construction Corps from January 2015 to December 2016 were selected. According to random number table method, they were divided into observation group and control group, with 27 cases in each group. The observation group was treated by transjugular intrahepatic portosystemic shunt, and the control group was treated by pericardial devascularization. The operation effect, hemodynamic indexes and liver function indexes before and after operation of two groups were compared, and the incidence of adverse events after operation was observed. Results There was no significant difference in total clinical effective rate between the two groups (P ＞ 0.05). After operation, the diameter of portal vein, portal vein blood flow, splenic vein diameter and splenic vein blood flow in observation group were lower than those of control group, while the portal venous flow velocity and the splenic vein velocity were higher than those of control group, the differences were statistically significant (P ＜ 0.05). After operation, the levels of alanine transaminase, aspartate aminotransferase and total bilirubin in observation group were lower than those of control group (P ＜ 0.05). The incidence of adverse events in observation group was significantly lower than that in control group (P ＜ 0.05). Conclusion Transjugular intrahepatic portosystemic shunt is effective in the treatment of cirrhosis with portal hypertension. It can significantly improve the hemodynamic indexes and liver function, and reduce the incidence of postoperative adverse events.
|
|
|
|
|
|
[1] 邵庆华，郑盛，杨涓，等.经颈静脉肝内门体分流术联合胃冠状静脉栓塞术治疗肝硬化门静脉高压症上消化道出血中远期疗效评价[J].肝脏，2016，21（1）：17-20.
[2] Qi X，Tian Y，Zhang W，et al. Covered versus bare stents for transjugular intrahepatic portosystemic shunt：an updated meta-analysis of randomized controlled trials [J]. Therap Adv Gastroenterol，2017，10（1）：32-41.
[3] 薛挥，李培杰，李伟之，等.经颈静脉肝内门体分流术的并发症及其防治[J].临床肝胆病杂志，2016，32（2）：238-241.
[4] 亓皓亮，王广川，张明艳，等.Viatorr覆膜支架在经颈静脉肝内门体静脉分流术中的临床应用[J].中华消化病与影像杂志：电子版，2017，7（5）：200-204.
[5] Busk TM，M?覬ller S，Bendtsen F. Cardiovascular Effects of a Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis [J]. Current Hepatology Reports，2017， 16（3）：250-257.
[6] 李雷.采用双支架技术行经颈静脉肝内门体静脉分流术（TIPS）治疗门脉高压症的临床研究[D].太原：山西医科大学，2016.
[7] 杨镇.我国门静脉高压症外科治疗的现况和展望[J].临床肝胆病杂志，2016，32（2）：250-253.
[8] 王磊，王文卿.经颈静脉肝内门体分流术治疗老年肝硬化门静脉高压症的疗效及对血流动力学的影响[J].临床外科杂志，2018，26（1）：47-50.
[9] 申权，杨维竹，江娜，等.经颈静脉肝内门体分流术治疗门静脉海绵样变并发门静脉高压[J].中国介入影像与治疗学，2016，13（11）：658-661.
[10] Fares N，Robic MA，Péron JM，et al. Transjugular intrahepatic portosystemic shunt placement before abdominal intervention in cirrhotic patients with portal hypertension：lessons from a pilot study [J]. Eur J Gastroenterol Hepatol，2018，30（1）：21-26.
[11] 李臻，李磊，韩新巍，等.经皮经肝穿刺肝内支架轨道重建治疗经颈静脉肝内门体支架分流术后分流道闭塞[J].中华消化外科杂志，2016，15（7）：748-750.
[12] 徐征国，赵泳冰，郑媛钰，等.肝硬化患者经颈静脉肝内门体分流术后门静脉压力下降梯度与预后的关系[J].临床肝胆病杂志，2016，32（12）：2326-2330.
[13] Tsauo J，Shin JH，Han K，et al. Transjugular Intrahepatic Portosystemic Shunt for the Treatment of Chylothorax and Chylous Ascites in Cirrhosis：A Case Report and Systematic Review of the Literature [J]. J Vasc Interv Radiol，2016，27（1）：112-116.
[14] 刘永生，吴聪，涂旺招，等.改良型选择性贲门周围血管离断术治疗门静脉高压症临床疗效分析[J].中国现代医生，2016，54（33）：43-46.
[15] 付旭锋，陈冰冰，严亚萍，等.动物模型在间充质干细胞治疗慢性肝病临床前研究的应用[J].中国实验动物学报，2017，25（1）：102-106.
[16] 冯小嫦.经颈静脉肝内门体分流术治疗肝硬化门静脉高压患者的临床效果观察[J].中国医学创新，2016，13（4）：119-121.
[17] Bureau C，Thabut D，Oberti F，et al. Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-free Survival of Patients With Cirrhosis and Recurrent Ascites [J]. Gastroenterology，2017， 152（1）：157-163.
[18] 袁星.影响肝硬化门静脉高压症患者术后并发症发生的相关因素[J].中国当代医药，2017，24（3）：51-53.
[19] 肖江强，诸葛宇征.经颈静脉肝内门体分流术研究进展及其在肝硬化门静脉高压治疗中的应用[J].临床肝胆病杂志，2016，32（2）：234-237.
[20] 巴音达拉，陈凯，苏洪德，等.不同手术方式治疗肝硬化门静脉高压并发上消化道出血的对照研究[J].中西医结合肝病杂志，2017，27（5）：286-288.
[21] Allegretti AS，Ortiz G，Cui J，et al. Changes in Kidney Function After Transjugular Intrahepatic Portosystemic Shunts Versus Large-Volume Paracentesis in Cirrhosis：A Matched Cohort Analysis [J]. Am J Kidney Dis，2016，68（3）：381-391.
[22] Meng J，Wang Q，Liu K，et al. Systemic and Splanchnic Lipopolysaccharide and Endothelin-1 Plasma Levels in Liver Cirrhosis before and after Transjugular Intrahepatic Portosystemic Shunt [J]. Gastroenterol Res Pract，2016， 2016：1-5.
[23] 邓小红，周林，肖修林，等.完全腹腔镜脾切除加贲门周围血管离断术治疗肝硬化门静脉高压症效果分析[J].中国当代医药，2016，23（36）：33-35，41.
[24] 杨卫生，郭武华.肝硬化门静脉高压症患者肝脏血流动力学指标与门静脉压力的相关性研究[J].中国全科医学，2016，19（23）：2784-2788. |
|
|
|
